
**Claims**

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:





(I)

wherein:

$R^1$ is selected from the group consisting of hydrogen, halogen, a substituted or unsubstituted $C_1$-$C_6$ alkyl, a substituted or unsubstituted $C_1$-$C_6$ haloalkyl, a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl, a substituted or unsubstituted $C_1$-$C_6$ alkoxy, an unsubstituted mono-$C_1$-$C_6$ alkylamine and an unsubstituted di-$C_1$-$C_6$ alkylamine;

each $R^2$ is independently selected from the group consisting of halogen, a substituted or unsubstituted $C_1$-$C_6$ alkyl, a substituted or unsubstituted $C_1$-$C_6$ haloalkyl and a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl; or

when m is 2 or 3, each $R^2$ is independently selected from the group consisting of halogen, a substituted or unsubstituted $C_1$-$C_6$ alkyl, a substituted or unsubstituted $C_1$-$C_6$ haloalkyl and a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl, or two $R^2$ groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl or a substituted or unsubstituted 3 to 6 membered heterocyclyl;

$R^3$ is selected from the group consisting of X-$R^{3A}$,  and ;

$R^{3A}$ is a substituted or unsubstituted 5 to 10 membered heteroaryl;

$R^4$ is selected from the group consisting of $NO_2$, $S(O)R^6$, $SO_2R^6$, halogen, cyano and an unsubstituted $C_1$-$C_6$ haloalkyl;

$R^5$ is ~~selected from the group consisting of~~ $X^1$-$(Alk^1)_n$-$R^7$;

$Alk^1$ is selected from an unsubstituted $C_1$-$C_4$ alkylene and a $C_1$-$C_4$ alkylene substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, an unsubstituted $C_1$-$C_3$ alkyl and an unsubstituted $C_1$-$C_3$ haloalkyl;

$R^6$ is selected from the group consisting of a substituted or unsubstituted $C_1$-$C_6$ alkyl, a substituted or unsubstituted $C_1$-$C_6$ haloalkyl and a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl;

$R^7$ is selected from ~~a substituted or unsubstituted $C_1$-$C_6$ alkoxy,~~ a substituted or unsubstituted $C_3$-$C_{10}$ cycloalkyl~~,~~ and a substituted or unsubstituted 3 to 10 membered heterocyclyl~~, hydroxy, amino, a substituted or unsubstituted mono-substituted amine group, a substituted or unsubstituted di-substituted amine group, a substituted or unsubstituted N-carbamyl, a substituted or unsubstituted C-amido and a substituted or unsubstituted N-amido~~;

m is 0, 1, 2 or 3;

n is selected from 0 and 1;

$X^1$ is –NH-; and

X is selected from the group consisting of –O–, –S– and –NH–.

2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ is -$CH_2F$ or –$CF_3$.

3. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ is -$CHF_2$.

4. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^1$ is not $-CH_2F$, $-CHF_2$ or $-CF_3$.

5. The compound of any one of Claims 1-4, or a pharmaceutically acceptable salt thereof, wherein m is 1.

6. The compound of any one of Claims 1-4, or a pharmaceutically acceptable salt thereof, wherein m is 2.

7. The compound of any one of Claims 1-4, or a pharmaceutically acceptable salt thereof, wherein m is 3.

8. The compound of any one of Claims 1-7, or a pharmaceutically acceptable salt thereof, wherein one $R^2$ is an unsubstituted $C_1$-$C_6$ alkyl and any other $R^2$, if present, is independently selected from the group consisting of halogen, a substituted or unsubstituted $C_1$-$C_6$ alkyl, a substituted or unsubstituted $C_1$-$C_6$ haloalkyl and a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl.

9. The compound of any one of Claims 1-8, or a pharmaceutically acceptable salt thereof, wherein each $R^2$ is independently an unsubstituted $C_1$-$C_6$ alkyl.

10. The compound of any one of Claims 1-4, 8 or 9, or a pharmaceutically acceptable salt thereof, wherein m is 2; and each $R^2$ is an unsubstituted methyl.


11. The compound of any one of Claims 1-4, or a pharmaceutically acceptable salt thereof, wherein m is 0.

12. The compound of any one of Claims 1-4 or 6, or a pharmaceutically acceptable salt thereof, wherein two $R^2$ groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl.


13. The compound of any one of Claims 1-4, 6-7 or 12, or a pharmaceutically acceptable salt thereof, wherein two $R^2$ groups taken together with the atom to which they are attached form an unsubstituted cyclopropyl.

14. The compound of any one of Claims 1-4 or 6-7, or a pharmaceutically acceptable salt thereof, wherein two $R^2$ groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted 3 to 6 membered heterocyclyl.


15. The compound of any one of Claims 1-4, that is also a compound of Formula (Ia), Formula (Ib), Formula (Ic) or Formula (Id):




**(Ia)**



**(Ib)**




**(Ic)**




**(Id)**

or pharmaceutically acceptable salts of any of the foregoing.

16. The compound of any one of Claims 1-15, wherein $R^3$ is $X\text{-}R^{3A}$.

17. The compound of any one of Claims 1-16, wherein $R^{3A}$ is .


18. The compound of any one of Claims 1-16, wherein $R^{3A}$ is .


19. The compound of any one of Claims 1-16, wherein $R^{3A}$ is a substituted 5 to 10 membered heteroaryl.

20. The compound of any one of Claims 1-19, wherein X is –O–.

21. The compound of any one of Claims 1-19, wherein X is –S–.

22. The compound of any one of Claims 1-19, wherein X is –NH–.

23. The compound of any one of Claims 1-15, wherein $R^3$ is .

24. The compound of any one of Claims 1-15, wherein $R^3$ is .

25. The compound of any one of Claims 1-24, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is $NO_2$.

26. The compound of any one of Claims 1-24, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is cyano.

27. The compound of any one of Claims 1-24, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is halogen.

28. The compound of any one of Claims 1-24, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is an unsubstituted $C_1$-$C_6$ haloalkyl.

29. The compound of any one of Claims 1-24 or 28, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is $–CF_3$.

30. The compound of any one of Claims 1-24, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is $S(O)R^6$.

31. The compound of any one of Claims 1-24, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is $SO_2R^6$.

32. The compound of any one of Claims 1-24 or 30-31, or a pharmaceutically acceptable salt thereof, wherein $R^6$ is a substituted or unsubstituted $C_1$-$C_6$ alkyl.


33. The compound of any one of Claims 1-24 or 30-31, or a pharmaceutically acceptable salt thereof, wherein $R^6$ is a substituted or unsubstituted $C_3$-$C_6$ cycloalkyl.

34. The compound of any one of Claims 1-24 or 30-31, or a pharmaceutically acceptable salt thereof, wherein $R^6$ is a substituted or unsubstituted $C_1$-$C_6$ haloalkyl.


35. The compound of any one of Claims 30-31 or 34, or a pharmaceutically acceptable salt thereof, wherein $R^6$ is $–CF_3$.


~~36. The compound of any one of Claims 1-35, or a pharmaceutically acceptable salt thereof, wherein $R^5$ is $–X^1-(Alk^1)_n-R^7$.~~

~~37.~~36. The compound of any one of Claims 1-~~36~~35, or a pharmaceutically acceptable salt thereof, wherein $Alk^1$ is unsubstituted $–(CH_2)_{1-4}–$* for which "*" represents the point of attachment to $R^7$.

~~38.~~37. The compound of any one of Claims 1-~~36~~35, or a pharmaceutically acceptable salt thereof, wherein $Alk^1$ is selected from .

~~39.~~38. The compound of any one of Claims 1-~~36~~35, or a pharmaceutically acceptable salt thereof, wherein $Alk^1$ is a substituted  for which "*" represents the point of attachment to $R^7$.

~~40.~~39. The compound of any one of Claims 1-~~36~~ 35 or ~~39~~38, or a pharmaceutically acceptable salt thereof, wherein $Alk^1$ is selected from: .


and .

~~41.~~40. The compound of any one of Claims 1-~~40~~39, or a pharmaceutically acceptable salt thereof, wherein n is 1.

~~42.~~41. The compound of any one of Claims 1-~~36~~35, or a pharmaceutically acceptable salt thereof, wherein n is 0.

~~43. The compound of any one of Claims 1-42, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a substituted or unsubstituted mono-substituted amine group.~~

~~44. The compound of any one of Claims 1-42, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a substituted or unsubstituted di-substituted amine group.~~

~~45. The compound of any one of Claims 1-42, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is selected from a substituted or unsubstituted N-carbamyl, a substituted or unsubstituted C-amido and a substituted or unsubstituted N-amido.~~

~~46.~~42. The compound of any one of Claims 1-~~42~~41, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a substituted or unsubstituted $C_3$-$C_{10}$ cycloalkyl.

~~47.~~43. The compound of any one of Claims 1-~~42 or 46~~42, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a substituted or unsubstituted $C_6$-$C_{10}$ spirocycloalkyl.

~~48.~~44. The compound of any one of Claims 1-~~42~~41, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a substituted or unsubstituted 3 to 10 membered heterocyclyl.

~~49.~~45. The compound of any one of Claims 1-~~42~~ 41 or ~~48~~44, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is a substituted or unsubstituted 6 to 10 membered spiro heterocyclyl.


~~50. The compound of any one of Claims 1-42, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is hydroxy or amino.~~









~~51.~~46. The compound of any one of Claims 1-~~50~~45, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is unsubstituted.






~~52.~~47. The compound of any one of Claims 1-~~50~~45, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is substituted.

~~53.~~48. The compound of any one of Claims 1-~~49~~ 45 or ~~52~~47, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is substituted with 1 or 2 substituents independently selected from an unsubstituted $C_1$-$C_6$ alkyl, an unsubstituted $C_1$-$C_6$ alkoxy, fluoro, chloro, hydroxy and -$SO_2$-(unsubstituted $C_1$-$C_6$ alkyl).



~~54.~~49. The compound of any one of Claims 1-~~42~~41, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is selected from:











, , , , , ,  and .







~~55.~~50. The compound of any one of Claims 1-~~42~~41, or a pharmaceutically acceptable salt thereof, wherein $R^7$ is selected from: , , ,  and .







~~56.~~51. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:







, ,







, ,








,

,

,

,

,

,








,

,

,

,

,

,







,

,

,

,

,

,


,

,

,

,

.

,




,

,

,

,

,

,


,

,

,

,

,

,



,

,

,

,

,

,


,

,

,

, and

.


~~57.~~52. The compound of Claim ~~56~~51, wherein the compound is selected from the group consisting of:


and , or a pharmaceutically acceptable salt of any of the foregoing.





53. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.





54. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.


55. The compound of Claim 51, wherein the compound is  or a pharmaceutically acceptable salt thereof.


56. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.

57. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.

58. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.

59. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.

60. The compound of Claim 51, wherein the compound is , or a pharmaceutically acceptable salt thereof.

~~58.~~61. The compound of Claim 51, wherein the compound is 
, or a pharmaceutically acceptable salt thereof.

~~59.~~62. A pharmaceutical composition comprising an effective amount of the compound of any one of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

~~60.~~63. Use of an effective amount of a compound of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim ~~58~~ 62 in the manufacture of a medicament for treating a cancer or a tumor, wherein the cancer or the tumor is selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

~~61.~~64. Use of an effective amount of a compound of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim ~~58~~ 62 in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or the tumor is due to a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

~~62.~~65. Use of an effective amount of a compound of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim ~~58~~ 62 in the manufacture of a medicament for treating a malignant growth or a tumor, wherein the malignant growth or the tumor is due to a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an

esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

~~63.~~66. Use of a compound of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim ~~58~~62, and an effective amount of a HIV latency reversing agent, or a pharmaceutically acceptable salt thereof, for preparing a medicament for treating a HIV infection.

~~64.~~67. Use of a compound of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim ~~58~~62, and an effective amount of a HIV latency reversing agent, or a pharmaceutically acceptable salt thereof, for preparing a medicament for reducing the reoccurrence of a HIV infection.

~~65.~~68. Use of a compound of any one of Claims 1-~~57~~61, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim ~~58~~62, and an effective amount of a HIV latency reversing agent, or a pharmaceutically acceptable salt thereof, for preparing a medicament suitable for use in reducing the population of HIV infected cells.

~~66.~~69. The use of Claim ~~64~~68, wherein the cells are CD4+T cells.

~~67.~~70. The use of any one of Claims ~~62-64~~ 66-68, wherein the HIV latency reversing agent is selected from: a protein kinase C agonist, a PD-1 inhibitor, a PD-L1 inhibitor, an HDAC inhibitor, a phorbol ester and a bromodomain inhibitor.

~~68.~~71. The use of Claim ~~66~~70, wherein the HIV latency reversing agent is selected from: ingenol, rostatin, nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, PDR001, REGN2810, MEDI0680, Durvalumab, Atezolizumab, Avelumab, BMS-936559, BGB-A317, vorinostat, panobinostat, valproic acid, romidepsin, prostratin, phorbol 12-myristate-13-acetate, bryostatin-1, (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate, JQ1, I-BET762, OTX015, I-BET151, CPI203, PFI-1, MS436, CPI-0610, RVX2135, FT-1101, BAY1238097, INCB054329, TEN-010, GSK2820151, ZEN003694, BAY-299, BMS-986158, ABBV-075 and GS-5829.

~~69.~~72. The use of any one of Claims ~~62-67~~66-71, further comprising the use of one or more agents selected from the group consisting of a non-nucleoside reverse transcriptase inhibitor (NNRTI), a nucleoside reverse transcriptase inhibitor (NRTI), a protease inhibitor (PI), a fusion/entry inhibitor, an integrase strand transfer inhibitor (INSTI), a HIV vaccine, a HIV other antiretroviral therapy compound and combinations thereof, or a pharmaceutically acceptable salt of any of the aforementioned.